Myovant Sciences Ltd. (MYOV)
Company Description
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men.
The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer.
It is also developing MVT-602, an oligopeptide kisspeptin agonist, which is in Phase II clinical trial for the treatment of female infertility as part of assisted reproduction.
Myovant Sciences Ltd. has collaboration with Pfizer Inc. to develop and commercialize relugolix in oncology and women's health.
The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016.
The company was incorporated in 2016 and is based in London, the United Kingdom.
Myovant Sciences Ltd. is a subsidiary of Sumitovant Biopharma Ltd.
| Country | GB |
| IPO Date | Oct 27, 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 579 |
| CEO | David C. Marek |
Contact Details
Address: 11-12 St. James’s Square London, GB | |
| Website | https://myovant.com |
Stock Details
| Ticker Symbol | MYOV |
| Exchange | NYSE |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| CIK Code | 0001679082 |
| CUSIP Number | G637AM102 |
| ISIN Number | BMG637AM1024 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| David C. Marek | Chief Executive Officer & Director |
| Albert Liao | Director of Corporation Communications |
| Ann Tomlin | Senior Vice President of HR |
| Bryan Selby | Senior Vice President of Product Devel. |
| Dr. Andria Langenberg M.D. | Head of Drug Safety & Pharmacovigilance |
| Dr. Juan Camilo Arjona Ferreira M.D. | Chief Medical Officer |
| Jeffrey D. Nornhold | Senior Vice President of Pharmaceutical Operations & Devel. |
| Lauren Merendino | Chief Commercial Officer |
| Matthew Lang J.D. | Gen. Counsel & Corporation Sec. |
| Uneek Mehra | Principal Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 20, 2023 | 15-12G | Filing |
| Mar 10, 2023 | 25-NSE | Filing |
| Mar 10, 2023 | 4 | Filing |
| Mar 10, 2023 | 4 | Filing |
| Mar 10, 2023 | 4 | Filing |
| Mar 10, 2023 | 4 | Filing |
| Mar 10, 2023 | S-8 POS | Filing |
| Mar 10, 2023 | S-8 POS | Filing |
| Mar 10, 2023 | S-8 POS | Filing |
| Mar 10, 2023 | S-8 POS | Filing |